Acta Med. 2007, 50: 113-118
https://doi.org/10.14712/18059694.2017.66
Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study
References
1. Biochem Soc Trans 1997; 25: 705–8.
< DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anticancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. https://doi.org/10.1042/bst0250705>
2. Blood 2004; 104:2635–42.
< G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. https://doi.org/10.1182/blood-2004-03-1110>
3. J Clin Oncol 1999; 17:1244. Erratum in: J Clin Oncol 2000;18:2351.
< BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippstein D, Hiddemann W, Castelino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non- Hodgkin’s lymphomas. https://doi.org/10.1200/JCO.1999.17.4.1244>
4. J Clin Oncol 2003; 21:2457–9.
< B. Increasing chemotherapy intensity in aggressive lymphomas: a renewal? https://doi.org/10.1200/JCO.2003.93.116>
5. Semin Oncol 2004; 31(1 Suppl. 2):7–11.
< B. Effective immunochemotherapy for aggressive non-Hodgkin’s lymphoma. https://doi.org/10.1053/j.seminoncol.2003.12.003>
6. Curr Hematol Rep 2005; 4:7–14.
B. Treatment of diffuse large B-cell lymphoma.
7. Blood 1998; 92: 1927–32.
B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Rituximab (anti- CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
8. N Engl J Med 2002; 346:235–42.
< B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. https://doi.org/10.1056/NEJMoa011795>
9. Lancet 1975; 1:248–50.
< VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. https://doi.org/10.1016/S0140-6736(75)91142-3>
10. J Clin Oncol 2005; 23:4117–26.
< P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. https://doi.org/10.1200/JCO.2005.09.131>
11. Ann Oncol 1994; 5(Suppl. 2):91–95.
< RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA JR, Miller TP. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin’s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. https://doi.org/10.1093/annonc/5.suppl_2.S91>
12. Expert Rev Anticancer Ther 2003; 3:767–79.
< AJ. Rituximab (Rituxan/MabThera): the first decade (1993–2003). https://doi.org/10.1586/14737140.3.6.767>
13. Semin Oncol 2000; 27(6 Suppl. 12):9–16.
AJ. Rituximab: an insider’s historical perspective.
14. Blood 2003; 102(Suppl.):6a (abstract 8).
TM, Weller EA, Morrison VA, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne RD, Woda B, Fisher RI, Peterson BA, Horning SJ. Phase III trial of rituximab- CHOP (R-CHOP) vs. CHOP with second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL).
15. J Clin Oncol 2006; 24:3121–7.
< TM, Weller EA, Morrison WA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SH, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. https://doi.org/10.1200/JCO.2005.05.1003>
16. J Am Stat Assoc 1958; 53:457–81.
< EL, Meier P. Nonparametric estimation from incomplete observations. https://doi.org/10.1080/01621459.1958.10501452>
17. J Clin Oncol 1998; 16:2825–33.
< P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program. https://doi.org/10.1200/JCO.1998.16.8.2825>
18. Lancet Oncol 2006; 7:379–91.
< M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M;Mabthera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. https://doi.org/10.1016/S1470-2045(06)70664-7>
19. Blood 2004; 104:634–41.
< M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M: German High-Grade Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. https://doi.org/10.1182/blood-2003-06-2095>
20. Blood 2005; 106(Suppl.): 9a (abstract 13).
M, Kloess M, Schmits R, Zeynalova S, Lengfelder E, Franke A, Steinhauer H, Reiser M, Clemens M, Nickenig C, De Wit M, Hoffmann M, Mertelsmann R, Metzner B, Ho A, Truemper L, Eimermacher H, Mergenthaler H, Liersch R, Duehrsen U, Balleisen L, Hartmann F, Poeschel V, Schmitz N, Loeffler M. Six, not eight cycles of bi-weekly CHOP with rituximab (R CHOP- 14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL).
21. Ann Oncol 2005; 165(Suppl. 5):v175–v176 (abstract 473).
R, Trněný M, Belada D, Kubáčková K, Vášová I, Jankovská M, Klener P, for the Czech Lymphoma Study Group. Treatment of 101 high-risk aggressive Bcell lymphoma patients with MegaCHOP-BEAM regimen ± rituximab: the evolution of the concept.
22. J Clin Oncol 2006; 24(Suppl. 128S) (abstract 7577).
EL, Greco FA, Spigel DR, Doss HH, Farley C, Saez R, Kommor M, Hainsworth JD. Brief duration rituximab(R)/chemotherapy (CNOP or CVP) followed by maintenance rituximab in elderly/poor performance status patients (pts) with diffuse large B-cell lymphoma (DLBCL): a phase II trial of the Minnie Pearl Cancer Research Network.
23. J Clin Oncol 2005; 23:5027–33.
< LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O’Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. https://doi.org/10.1200/JCO.2005.09.137>
24. Hematol Oncol Clin North Am 2005; 19:611–27.
< GD, Deangelis LM. Treatment of primary central nervous system lymphoma. https://doi.org/10.1016/j.hoc.2005.05.002>
25. Oncology (Williston Park) 2005; 19(4 Suppl. 1);16–22.
R, Schmitz N, Pfreundschuh M;German High-Grade Non-Hodgkin’s Lymphoma Study Group. The best treatment for diffuse large B-cell lymphoma: a German perspective.
26. Pathologe 2000; 21:101–5.
< H. The new WHO classification of malignant lymphoma. After “REAL” a further step on the road to a worldwide consensus. https://doi.org/10.1007/s002920050377>
27. Leuk Lymphoma 2005; 46:1569–73.
< JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. https://doi.org/10.1080/10428190500217312>
28. J Clin Oncol 2001; 19:389–97.
< JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non- Hodgkin’s lymphoma. https://doi.org/10.1200/JCO.2001.19.2.389>